

29 August 2019

Auckland DHB
Chief Executive's Office
Level 1
Building 37
Auckland City Hospital
PO Box 92189
Victoria Street West
Auckland 1142



Re: Official Information Act request – Protocol for diagnosing primary Aldosteronism

I refer to your Official Information Act request dated 15 August 2019 requesting the following information

I am writing to request the ADHB protocol for diagnosing primary Aldosteronism. I also ask for a copy of the interpretation of the results of the test as well.

Primary aldosteronism (PA) is suspected in patients with hypertension resistant to usual anti-hypertensive drugs, especially those < 40 yrs or with hypokalaemia. Screening is by measurement of the serum aldosterone / renin ratio and confirmation by a test of aldosterone autonomy.

We use the attached saline infusion test (SIT) wherein 2 litres of normal saline is infused over 4 hours. While a non-suppressible result is a serum aldosterone value > 200 pmol/l in our laboratory, it is recognised that there is a grey area around this number and values > 180 pmol/l represent partial autonomy. The lower the value < 180 pmol/l, the less likely PA is present.

Persons with adrenal autonomy are then usually advised to have an adrenal CT scan. Depending on the result and individualised discussion with an endocrinologist, consideration is given to medical treatment versus further investigation by bilateral adrenal vein sampling to assess lateralisation with a view to adrenal surgery.

I trust this information answers your questions.

You are entitled to seek a review of the response by the Ombudsman under section 28(3) of the Official Information Act. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Please note that this response, or an edited version of this response, may be published on the Auckland DHB website.

Yours faithfully

Ailsa Claire, OBE

Chief Executive

Overview

Document Type	Guideline
Function	Clinical Service Delivery
Healthcare Service Group (HSG)	Adult Health
Department(s) affected	Endocrinology
Patients affected (if applicable)	Adult endocrinology patients
Staff members affected	ADHB clinicians in endocrinology
Key words	n/a
Author – role only	Endocrine Nurse Specialist
Owner (see ownership structure)	Clinical Director, Endocrinology
Edited by	Clinical Policy Advisor
Date first published	October 2001
Date this version published	November 2015
Review frequency	3 yearly
Unique Identifier	PP2006/RBP/023

Objective

- To assess autonomous aldosterone production i.e. adenoma or hyperplasia
- Confirmatory random aldosterone/renin ratio

Continued on next page

Section:	Clinical Procedures / RBP	Issued by:	Endocrine Nurse Specialist
File:	SalineInfTestAldosteronism2015-11-09.docx	Authorised by:	Clinical Director Endocrinology
	PP2006RBP/023		Reviewed November 2015

Overview, Continued

Associated Documents

The table below indicates other documents associated with this guideline.

Туре	Document Titles
ADHB Policies	Hand Hygiene Infection Control
and Guidelines	Infection Prevention & Control
Library	• <u>Informed Consent</u>
	 <u>Intravenous Catheters - Peripheral</u>
	Medications - Administration
	Standard Precautions - Infection Control
	<u>Tikanga Best Practice</u>
References	Endocrine & Metabolic Testing Manual Third
	Edition 1998: 1-17
	 Holland Hypertension 1984, 6:717
	• Journal of Hypertension 2007,25:1433-1442
	Saline Infusion Test performance in the PA
	prevalence in hypertensives (PAPY) study:

Section:Clinical Procedures / RBPIssued by:Endocrine Nurse SpecialistFile:SalineInfTestAldosteronism2015-11-09.docxAuthorised by:Clinical Director EndocrinologyClassification:PP2006RBP/023Date Issued:Reviewed November 2015

Saline Infusion Test for Aldosteronism - Process

Stage	Description	
Indication	Raised aldosterone/renin ratio with plasma aldosterone > 400 nmol/L	
Contra-indication	Patients with congestive heart failure or inability to tolerate high volume fluid infusions. Hypokalaemia should be pre treated	
Preparation	 Patient must be off for 4 - 6 weeks: Amiloride, Spironolactone Spirotone Amizide, Moduretic, Frumil, Aldactone, check with endocrine consultant regarding possible changes in medication pre testing Maintain potassium supplement medication Bring all medications 	
Equipment	 IV equipment 4 x 500 ml bags of 0.9% NaCl Blood tubes clearly labelled Sphygmomanometer, stethoscope & BP chart 	
Procedure	 Check and document regular patient anti-hypertensive medication has been taken; Beta-blockers, diuretics, ACE inhibitors, ARBs, calcium channel blockers and NSAID Insert IV line, withdraw basal bloods and send sample for an urgent serum potassium level; Commence infusion (500 mls 0.9% NaCl/hour for 4 hours = 2L); Take BP hourly; Continue normal saline infusion 500 ml/hr over 4 hours; Encourage the patient to pass urine prior to lying down for the last hour of infusion; For the final hour of infusion the patient must be supine. The final blood sample can be taken earlier while supine if the patient needs to get up to the toilet before finishing the infusion i.e. up to 3½hrs; Record hourly BP, assess patient's breathing and report acute breathlessness/chest tightness; Plus 4 hour blood sample (allow 5ml waste). 	

Continued on next page

Section:	Clinical Procedures / RBP	Issued by:	Endocrine Nurse Specialist
File:	SalineInfTestAldosteronism2015-11-09.docx		
Classification:			Reviewed November 2015

Saline Infusion Test for Aldosteronism - Process, Continued

Stage	Description
Samples	 Basal – sodium, potassium, creatinine, Aldosterone, Renin + 4 hours – Aldosterone only NB Aldosterones need to be in to the laboratory within 2 hours
Interpretation	 Aldosterone/renin ratio > 40 = consistent with hyperaldosteronism = screening test only The suppression test for autonomous aldosterone production: Normal subjects - plasma aldosterone < 200 pmol/L Hyperaldosteronism - plasma aldosterone > 200 pmol/L Failure to suppress also occurs in a proportion of patients with hypertension and reduced Glomerular filtration rate.

Section:Clinical Procedures / RBPIssued by:Endocrine Nurse SpecialistFile:SalineInfTestAldosteronism2015-11-09.docxAuthorised by:Clinical Director EndocrinologyClassification:PP2006RBP/023Date Issued:Reviewed November 2015